In a report released today, Susan Anderson from Canaccord Genuity reiterated a Buy rating on Niagen Bioscience, with a price target of $16.00. The company’s shares closed yesterday at $7.26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Anderson is a 5-star analyst with an average return of 17.7% and a 45.22% success rate. Anderson covers the Consumer Cyclical sector, focusing on stocks such as Ulta Beauty, Olaplex Holdings, and Sally Beauty.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Niagen Bioscience with a $15.55 average price target, an 114.19% upside from current levels. In a report released today, Roth MKM also maintained a Buy rating on the stock with a $23.00 price target.
Based on Niagen Bioscience’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $31.12 million and a net profit of $3.61 million. In comparison, last year the company earned a revenue of $22.74 million and had a GAAP net loss of $15 thousand
Read More on NAGE:
Disclaimer & DisclosureReport an Issue
- Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling
- Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
- Niagen Bioscience raises FY25 revenue view to up 25%-30% from up 22%-27%
- Niagen Bioscience’s Niagen IV, injections now available at iCRYO clinics
- Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/PayPal%20Holdings%20Inc%20HQ%20photo-by%20bennymarty%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)